Immunome Inc (IMNM) USD0.0001

- Add to watchlist
- This stock can be held in a




Business summary
Immunome Inc. is a biopharmaceutical company utilizing its human memory B cell platform to discover and develop antibody therapeutics. The Company’s primary focus is oncology. Its discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. Its lead oncology program is focused on IL-38. It is engaged in the research and development of the antibody mixture. IMM-BCP-01 is its lead infectious disease discovery program with a focus on SARS-CoV-2.
Contact details
Important dates
General stock information
- Short code:
- IMNM
- ISIN:
- US45257U1088
- Market cap:
- $295.95 million
- Shares in issue:
- 10.63 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.